ALK's adrenaline pen should become growth driver again
The CEO of Danish allergy group ALK expects the company’s adrenaline pen to return to being a major growth driver for the company, following massive challenges last year.
.jpg)
BY BENJAMIN WERNER CHRISTENSEN
Last year’s debacle that led to a recall of no less than 186,000 units of the insulin pen Jext is a closed chapter for the Danish-based allergy drug group ALK.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK: It shouldn’t be allowed to happen
For abonnenter
“It’s a very positive development”
For abonnenter
ALK brings in female EVP
For abonnenter
